$FBLG

FibroBiologics (Nasdaq: FBLG) reported preclinical results for fibroblast-spheroid-derived chondrocyte spheroids (FSdCS) in animals with induced joint defects. According to the company, a single injection led to cartilage repair within four weeks. The company says FSdCS manufacturing takes four days and could support a lower-cost, scalable biologic alternative to joint replacement.

FibroBiologics (Nasdaq: FBLG) reported Q2 2026 results and said it dosed the first patients in its Phase 1/2 trial of CYWC628 for diabetic foot ulcers. It completed cGMP manufacturing of three CYWC628 batches. The company raised $9.0 million via private placement and $3.0 million in a public offering. Q2 net loss was about $4.1 million, with cash of about $3.5 million at June 30, 2026.

FibroBiologics, Inc. (FBLG) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001958777 0001958777 2026-07-02 2026-07-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 02,

FibroBiologics, Inc. (FBLG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 5 fblg-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 25, 2026, between FibroBiologics, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified on the

FibroBiologics, Inc. (FBLG) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 fblg-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 FIBROBIOLOGICS, INC. 2026 EQUITY AND INCENTIVE COMPENSATION PLAN 1. Purpose . The purpose of this Plan is to permit award grants to Participants and to provide to such persons incentives and rewards for service and/or perform

FibroBiologics (NASDAQ:FBLG) said it has enrolled and dosed the first patients in its Phase 1/2 trial of CYWC628 for diabetic foot ulcers. The multicenter randomized study in Australia will enroll up to 120 patients to test safety, tolerability, and efficacy versus standard of care, with an interim analysis after 6 weeks. The company previously guided interim results for Q3 2026.

FibroBiologics (FBLG) CEO, O'HEERON PETE, was granted 92,410 stock options with an exercise price of $1.38 per share, expiring on May 4, 2036. The options will vest over four years, with one-quarter vesting on the one-year anniversary of the May 4, 2026 grant date, and the remainder in 36 equal monthly installments, contingent on continuous service. This transaction is a compensation grant, not a market purchase, and increases his direct derivative holdings to 92,410 options.

FibroBiologics announced its Q1 2026 financial results, reporting a net loss of $5 million and critical progress in its clinical trials. The company completed cGMP manufacturing and site onboarding for its Phase 1/2 clinical trial for CYWC628 in diabetic foot ulcers, aiming to dose the first patient in Q2 2026. FibroBiologics also regained Nasdaq compliance and expanded its patent portfolio, while raising an additional $2.5 million net in a recent direct offering.

FibroBiologics (FBLG) reported a net loss of $5.0 million for the quarter ended March 31, 2026, with cash and cash equivalents of only $1.5 million. The company faces significant going concern risk without additional capital, despite raising $0.7 million in March and $2.5 million net in April through equity offerings. FBLG is a pre-revenu medical research company focusing on fibroblast-based therapies and is advancing several programs towards clinical trials, but also disclosed a material weakness in its internal financial controls.

H.C. Wainwright has significantly increased its price target for FibroBiologics (NASDAQ:FBLG) shares from $4.00 to $8.00, while maintaining a Buy rating. This adjustment comes as the firm highlights the company's progress in its Phase 1/2 trial for fibroblast therapy in diabetic foot ulcer patients and anticipates key interim results in the first half of 2026. Despite a recent reverse stock split, a public offering, and a substantial stock price decline over the past year, H.C. Wainwright believes in the broader therapeutic potential of fibroblast therapy.